Ten new medicines including GlaxoSmithKline’s Tafinlar (dabrafenib) for metastatic melanoma, and Sanofi SA’s Lemtrada (alemtuzumab) for multiple sclerosis have been recommended for marketing by the European Medicines Agency. ---Subscribe to MedNous to access this article--- Regulation & Policy
